By Fineline Cube Sansure Biotech Inc. (SHA: 688289) announced that five of its nucleic acid diagnostic kits have obtained EU CE certification under the In Vitro Diagnostic Medical Devices Regulation (IVDR).
Regulatory Milestone
| Item | Detail |
|---|---|
| Company | Sansure Biotech Inc. (SHA: 688289) |
| Regulation | EU In Vitro Diagnostic Medical Devices Regulation (IVDR) |
| Certification Type | CE certification |
| Products Certified | 5 nucleic acid diagnostic kits |
| Announcement Date | 4 Aug 2026 |
Product Classification Details
- Class C Certification:
- Human Papillomavirus Genotyping Kit (Melting Curve Analysis)
- SARS-CoV-2, Influenza A/B & RSV Multiplex Nucleic Acid Diagnostic Kit (PCR-Fluorescence Probing)
- Class D Certification (Highest risk category – First batch for company):
- Human Immunodeficiency Virus Type 1 RNA Quantitative Fluorescence Diagnostic Kit (PCR-Fluorescence Probing)
- Hepatitis B Virus DNA Quantitative Fluorescence Diagnostic Kit (PCR-Fluorescence Probing)
- Hepatitis C Virus RNA Quantitative Fluorescence Diagnostic Kit (PCR-Fluorescence Probing)
Strategic Significance
The EU IVDR establishes more rigorous requirements for clinical evidence, post-market surveillance, and quality management systems compared to the previous In Vitro Diagnostic Directive (IVDD). Companies must demonstrate substantial clinical performance data and implement comprehensive risk management protocols.
Achieving Class D certification for three products represents a significant accomplishment, as this is the highest risk category under IVDR and requires the most stringent clinical validation and quality assurance measures. This positions Sansure among the first Chinese molecular diagnostics companies to successfully navigate the EU’s stringent IVDR requirements.
Market Opportunity & Competitive Landscape
- European IVD Market: Valued at over €25 billion annually with strong demand for high-quality molecular diagnostics
- Regulatory Barrier: IVDR implementation has created significant market entry barriers, with many competitors struggling to achieve compliance
- Competitive Positioning: Sansure’s successful certification demonstrates technical excellence and regulatory expertise
- Commercial Potential: Enhanced market access across all EU member states with premium positioning for high-complexity diagnostic tests
Company International Strategy
“The IVDR certification represents the highest standard of regulatory compliance in the European diagnostic market,” said Dai Lifu, Chairman and CEO of Sansure Biotech. “This accomplishment validates our commitment to quality, innovation, and patient safety while opening new opportunities across European healthcare systems.”
This regulatory milestone supports Sansure’s broader international growth strategy, which has seen the company expand its presence across Asia, Latin America, and now Europe. The company reported international revenue growth of over 40% year-over-year in its most recent financial results, driven by demand for advanced molecular diagnostic technologies.
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory achievements, market expansion, and commercial expectations. Actual results may differ due to regulatory changes, competitive pressures, market dynamics, and implementation challenges.-Fineline Info & Tech